HB0034 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 37 | Generalised pustular psoriasis | 1 |
37. Generalised pustular psoriasis
Clinical trials : 79 / Drugs : 57 - (DrugBank : 21) / Drug target genes : 20 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05512598 (ClinicalTrials.gov) | November 6, 2022 | 22/8/2022 | HB0034 in Patients With Generalized Pustular Psoriasis (GPP) | Multi-centre, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of HB0034 in Patients Acute Generalized Pustular Psoriasis (GPP) Flare | Generalized Pustular Psoriasis | Drug: HB0034 | Shanghai Huaota Biopharmaceutical Co., Ltd. | NULL | Recruiting | 18 Years | 75 Years | All | 10 | Phase 1 | China |